Ductal carcinoma in situ of the breast: The clinical significance of histological classification

Histopathology

Volumn 30, Issue 2, 1997, Pages 113-119

  Quinn, C M ^a   Ostrowski, J L ^a   Parkin, G J S ^a   Horgan, K ^a   Benson, E A ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

ductal carcinoma in situ (DCIS); early invasion; histological grade; local recurrence

Indexed keywords

ARTICLE; BREAST CARCINOMA; BREAST CARCINOMA IN SITU; CANCER CLASSIFICATION; CANCER INVASION; CANCER RECURRENCE; CARCINOMA IN SITU; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0031040279     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1997.d01-578.x     Document Type: Article

References (40)

1. Azzopardi JG. Epitheliosis and in situ carcinoma. In Bennington JL ed. Problems in Breast Pathology. Philadelphia: Saunders, 1979; 128-146.
2. Rogers I.W. Carcinoma in situ (CIS). In Page DL, Anderson TJ eds. Diagnostic Histopathology of the Breast. Edinburgh: Churchill Livingstone, 1987; 157-192.
3. Lagios MD, Margolin FR, Westdahl PR, Rose ME. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 1989; 63; 618-624.
4. Lagios MD. Duct carcinoma in situ. Pathology and treatment. Surg. Clin. North Am. 1990; 70; 853-871.
5. van Dongen JA, Holland R, Peterse JL et al. Ductal carcinoma in situ of the breast: second EORTC Consensus meeting. Eur. J. Cancer 1992; 28; 626-629.
6. Bellamy COC, McDonald C, Salter DM, Chetty U, Anderson TJ. Noninvasive ductal carcinoma of the breast: The relevance of histologic categorization. Hum. Pathol. 1993; 24; 16-23.
7. Solin LJ, Yeh I-T, Kurtz J et al. Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast-conserving surgery and definitive irradiation. Correlation of pathologic parameters with outcome of treatment. Cancer 1993; 71; 2532-2542.
8. Stomper PC, Connolly JL, Meyer JE, Harris JR. Clinically occult ductal carcinoma detected with mammography: Analysis of 100 cases with radiologic-pathologic correlation. Radiology 1989; 172; 235-241.
9. Bur ME, Zimarowski MJ, Schnitt SJ, Baker S, Lew R. Estrogen receptor immunohistochemistry in carcinoma in situ of the breast. Cancer 1992; 69; 1174-1181.
10. Meyer JS. Cell kinetics of histologic variants of in situ breast carcinoma. Breast Cancer Res. Treat. 1986; 7; 171-180.
11. Locker AP, Horrocks C, Gilmour AS et al. Flow cylometric and histologic analysis of ductal carcinoma in situ of the breast. Br. J. Surg. 1990; 77; 564-567.
12. Killeen JL, Namiki H. DNA analysis of ductal carcinoma in situ of the breast. A comparison with histological features. Cancer 1991; 68; 2602-2607.
13. Pallis L, Skoog L, Falkner U et al. The DNA profile of breast cancer in situ. Eur. J. Surg. Oncol. 1992; 18; 108-111.
14. van de Vijver MJ, Peterse JL, Mooi WJ et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. New Engl. J. Med. 1988; 319; 1239-1245.
15. Bartkova J, Barnes DM, Millis RR, Gullick WJ. Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. Hum. Pathol. 1990; 21; 1164-1167.
16. Ramachandra S, Machin L, Ashley S, Monaghan P, Gusterson BA. Immunohistochemical distribution of c-erbB-2 in in situ breast carcinoma - a detailed morphological analysis. J. Pathol. 1990; 161; 7-14.
17. Barnes DM, Meyer JS, Gonzalez JG, Gullick WJ, Millis RR. Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ. Breast Cancer Res. Treat. 1991; 18; 11-17.
18. Poller DN, Roberts EC, Bell JA, Elston CW, Blamey RW, Ellis IO. p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. Hum. Pathol. 1993; 24; 463-468.
19. Leal CB, Schmitt FC, Bento MJ, Maia NC, Lopes CS. Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy, and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein. Cancer 1995; 75; 2123-2131.
20. Lennington WJ, Jensen RA, Dalton LW, Page DL. Ductal carcinoma in situ of the breast. Heterogeneity of individual lesions. Cancer 1994; 73; 118-124.
21. Poller DN, Silverstein MJ, Galea M et al. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification. Association between cellular proliferation and c-erbB-2 protein expression. Mod. Pathol. 1994; 7; 257-262.
22. Silverstein MJ, Poller DN, Waisman JR et al. Prognostic classification of breast ductal carcinoma in situ. Lancet 1995; 345; 1154-1157.
23. Bobrow LG, Happerfield LC, Gregory WM, Millis RR. Ductal carcinoma in situ: Assessment of necrosis and nuclear morphology and their association with biological markers. J. Pathol. 1995; 176; 333-341.
24. Fisher ER, Costantino J, Fisher B, Palekar AS, Redmond C, Mamounas E. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol. B-17. Intraductal carcinoma (ductal carcinoma in situ). Cancer 1995; 75; 1130-1319.
25. Holland R, Peterse JL, Millis RR et al. Ductal carcinoma in situ: A proposal for a new classification. Semin. Diagn. Pathol. 1994; 11; 167-180.
26. Holland R, Hendriks JHCL. Microcalcifications associated with ductal carcinoma in situ: Mammographic-pathologic correlation. Semin. Diagn. Pathol. 1994; 11; 181-192.
27. Bobrow LG, Happerfield LC, Gregory WM, Springall RD, Millis RR. The classification of ductal carcinoma in situ and its association with biological markers. Semin. Diagn. Pathol. 1994; 11; 199-207.
28. Zafrani B, Leroyer A, Fourquet A et al. Mammographically detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases. Semin. Diagn. Pathol. 1994; 11; 208-214.
29. Lampejo OT, Barnes DM, Smith P, Millis RR. Evaluation of infiltrating ductal carcinomas with a DCIS component: Correlation of the histologic type of the in situ component with grade of the infiltrating component. Semin. Diagn. Pathol. 1994; 11; 215-222.
30. Cadman BA, Ostrowski JL, Quinn CM, DCIS subtype vs. IDC grade in tumours composed of ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC). Proceedings of the Pathological Society of Great Britain and Ireland. 173rd Meeting. July 1996.
31. Evans AJ, Pinder S, Ellis IO et al. Screening detected and symptomatic ductal carcinoma in situ: mammographic features with pathologic correlation. Radiology 1994; 191; 237-240.
32. Patchefsky AS, Schwartz GF, Finkelstein SD et al. Heterogeneity of intraductal carcinoma of the breast. Cancer 1989; 63; 731-741.
33. Schwartz GF, Patchefsky AS, Finkelstein SD et al. Nonpalpable in situ ductal carcinoma of the breast. Arch. Surg. 1989; 124; 29-32.
34. Ottesen GL, Graversen HP, Blichert-Toft M, Zedeler K, Andersen JA. Ductal carcinoma of the female breast. Short term results of a prospective nationwide study. Am. J. Surg. Pathol. 1992; 16; 1183-1196.
35. Silverstein MJ, Cohlan BF, Gierson ED et al. Duct carcinoma in situ: 227 cases without microinvasion. Eur. J. Cancer 1992; 28; 630-634.
36. Ashikari R, Hajdu SI, Robbins GF. Intraductal carcinoma of the breast. Cancer 1971; 28; 1182-1187.
37. Rosen PP, Braun D, Kinne DW. The clinical significance of preinvasive breast carcinoma. Cancer 1980; 46; 919-925.
38. Frykberg ER, Bland KI. Overview of the biology and management of ductal carcinoma in situ of the breast. Cancer 1994; 74; 350-361.
39. Arnesson LG, Smeds S, Fagerberg G, Grontoft O, Follow-up of two treatment modalities for ductal cancer in situ of the breast. Br. J. Surg. 1989; 76; 672-675.
40. Schwartz GF, Finkel GC, Garcia JC, Patchefsky AS. Subclinical ductal carcinoma in situ of the breast. Treatment by local excision and surveillance alone. Cancer 1992; 70; 2468-2474.